PubMed:12861174 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":164,"end":174},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":175,"end":399},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":400,"end":413},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":414,"end":562},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":563,"end":688},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":689,"end":697},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":698,"end":906},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":907,"end":1119},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1120,"end":1416},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1417,"end":1548},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1549,"end":1560},"obj":"Sentence"},{"id":"TextSentencer_T13","span":{"begin":1561,"end":1736},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T2","span":{"begin":164,"end":174},"obj":"Sentence"},{"id":"T3","span":{"begin":175,"end":399},"obj":"Sentence"},{"id":"T4","span":{"begin":400,"end":413},"obj":"Sentence"},{"id":"T5","span":{"begin":414,"end":562},"obj":"Sentence"},{"id":"T6","span":{"begin":563,"end":688},"obj":"Sentence"},{"id":"T7","span":{"begin":689,"end":697},"obj":"Sentence"},{"id":"T8","span":{"begin":698,"end":906},"obj":"Sentence"},{"id":"T9","span":{"begin":907,"end":1119},"obj":"Sentence"},{"id":"T10","span":{"begin":1120,"end":1416},"obj":"Sentence"},{"id":"T11","span":{"begin":1417,"end":1548},"obj":"Sentence"},{"id":"T12","span":{"begin":1549,"end":1560},"obj":"Sentence"},{"id":"T13","span":{"begin":1561,"end":1736},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.\nOBJECTIVE: The purpose of this study was to determine the concentrations of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in pregnancies that are complicated with primary antiphospholipid syndrome.\nSTUDY DESIGN: Longitudinal blood samples were collected from 8 weeks of gestation in 28 women with treated primary antiphospholipid syndrome and 19 control women. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 were measured by immunoradiometric assay.\nRESULTS: Three antiphospholipid syndrome pregnancies miscarried, four pregnancies had intrauterine growth restriction and preeclampsia, six pregnancies had a thrombotic event, and one pregnancy had abruptio placentae. Mean (+/-SD) birth weight in antiphospholipid syndrome group was 2867 +/- 914 g (control, 3492 +/- 527 g; P =.02), and the mean gestation at delivery was 36.5 +/- 5.2 weeks (control, 40.3 +/- 0.7 weeks; P =.002). Insulin-like growth factor binding protein-1 and insulin-like growth factor-I concentrations increased with gestational age in both groups (2.8% and 2.4% per week), but insulin-like growth factor binding protein-1 was 61% higher in the antiphospholipid syndrome group (95% CI, 16%-122%; P =.004). Insulin-like growth factor-I was not significantly different (8% higher in antiphospholipid syndrome; 95% CI, -10% to 30%; P =.41).\nCONCLUSION: Serum concentrations of insulin-like growth factor binding protein-1 are abnormal in the antiphospholipid syndrome group and may reflect abnormalities in trophoblast invasion."}

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":811,"end":823},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.\nOBJECTIVE: The purpose of this study was to determine the concentrations of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in pregnancies that are complicated with primary antiphospholipid syndrome.\nSTUDY DESIGN: Longitudinal blood samples were collected from 8 weeks of gestation in 28 women with treated primary antiphospholipid syndrome and 19 control women. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 were measured by immunoradiometric assay.\nRESULTS: Three antiphospholipid syndrome pregnancies miscarried, four pregnancies had intrauterine growth restriction and preeclampsia, six pregnancies had a thrombotic event, and one pregnancy had abruptio placentae. Mean (+/-SD) birth weight in antiphospholipid syndrome group was 2867 +/- 914 g (control, 3492 +/- 527 g; P =.02), and the mean gestation at delivery was 36.5 +/- 5.2 weeks (control, 40.3 +/- 0.7 weeks; P =.002). Insulin-like growth factor binding protein-1 and insulin-like growth factor-I concentrations increased with gestational age in both groups (2.8% and 2.4% per week), but insulin-like growth factor binding protein-1 was 61% higher in the antiphospholipid syndrome group (95% CI, 16%-122%; P =.004). Insulin-like growth factor-I was not significantly different (8% higher in antiphospholipid syndrome; 95% CI, -10% to 30%; P =.41).\nCONCLUSION: Serum concentrations of insulin-like growth factor binding protein-1 are abnormal in the antiphospholipid syndrome group and may reflect abnormalities in trophoblast invasion."}

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":811,"end":823},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.\nOBJECTIVE: The purpose of this study was to determine the concentrations of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in pregnancies that are complicated with primary antiphospholipid syndrome.\nSTUDY DESIGN: Longitudinal blood samples were collected from 8 weeks of gestation in 28 women with treated primary antiphospholipid syndrome and 19 control women. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 were measured by immunoradiometric assay.\nRESULTS: Three antiphospholipid syndrome pregnancies miscarried, four pregnancies had intrauterine growth restriction and preeclampsia, six pregnancies had a thrombotic event, and one pregnancy had abruptio placentae. Mean (+/-SD) birth weight in antiphospholipid syndrome group was 2867 +/- 914 g (control, 3492 +/- 527 g; P =.02), and the mean gestation at delivery was 36.5 +/- 5.2 weeks (control, 40.3 +/- 0.7 weeks; P =.002). Insulin-like growth factor binding protein-1 and insulin-like growth factor-I concentrations increased with gestational age in both groups (2.8% and 2.4% per week), but insulin-like growth factor binding protein-1 was 61% higher in the antiphospholipid syndrome group (95% CI, 16%-122%; P =.004). Insulin-like growth factor-I was not significantly different (8% higher in antiphospholipid syndrome; 95% CI, -10% to 30%; P =.41).\nCONCLUSION: Serum concentrations of insulin-like growth factor binding protein-1 are abnormal in the antiphospholipid syndrome group and may reflect abnormalities in trophoblast invasion."}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":25,"end":30},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":240,"end":245},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":1561,"end":1566},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":427,"end":432},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":896,"end":905},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1715,"end":1726},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"}],"text":"Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.\nOBJECTIVE: The purpose of this study was to determine the concentrations of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in pregnancies that are complicated with primary antiphospholipid syndrome.\nSTUDY DESIGN: Longitudinal blood samples were collected from 8 weeks of gestation in 28 women with treated primary antiphospholipid syndrome and 19 control women. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 were measured by immunoradiometric assay.\nRESULTS: Three antiphospholipid syndrome pregnancies miscarried, four pregnancies had intrauterine growth restriction and preeclampsia, six pregnancies had a thrombotic event, and one pregnancy had abruptio placentae. Mean (+/-SD) birth weight in antiphospholipid syndrome group was 2867 +/- 914 g (control, 3492 +/- 527 g; P =.02), and the mean gestation at delivery was 36.5 +/- 5.2 weeks (control, 40.3 +/- 0.7 weeks; P =.002). Insulin-like growth factor binding protein-1 and insulin-like growth factor-I concentrations increased with gestational age in both groups (2.8% and 2.4% per week), but insulin-like growth factor binding protein-1 was 61% higher in the antiphospholipid syndrome group (95% CI, 16%-122%; P =.004). Insulin-like growth factor-I was not significantly different (8% higher in antiphospholipid syndrome; 95% CI, -10% to 30%; P =.41).\nCONCLUSION: Serum concentrations of insulin-like growth factor binding protein-1 are abnormal in the antiphospholipid syndrome group and may reflect abnormalities in trophoblast invasion."}

{"project":"preeclampsia_genes","denotations":[{"id":"PD-PreeclampsiaGenes-B_T1","span":{"begin":31,"end":38},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T2","span":{"begin":64,"end":71},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T3","span":{"begin":246,"end":253},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T4","span":{"begin":279,"end":286},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T5","span":{"begin":569,"end":576},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T6","span":{"begin":602,"end":609},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T7","span":{"begin":1120,"end":1127},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T8","span":{"begin":1169,"end":1176},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T9","span":{"begin":1289,"end":1296},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T10","span":{"begin":1417,"end":1424},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T11","span":{"begin":1585,"end":1592},"obj":"HGNC:INS"},{"id":"PD-PreeclampsiaGenes-B_T12","span":{"begin":31,"end":57},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T13","span":{"begin":64,"end":90},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T14","span":{"begin":246,"end":272},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T15","span":{"begin":279,"end":305},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T16","span":{"begin":569,"end":595},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T17","span":{"begin":602,"end":628},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T18","span":{"begin":1120,"end":1146},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T19","span":{"begin":1169,"end":1195},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T20","span":{"begin":1289,"end":1315},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T21","span":{"begin":1417,"end":1443},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T22","span":{"begin":1585,"end":1611},"obj":"HGNC:IGF2"},{"id":"PD-PreeclampsiaGenes-B_T23","span":{"begin":31,"end":57},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T24","span":{"begin":64,"end":90},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T25","span":{"begin":246,"end":272},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T26","span":{"begin":279,"end":305},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T27","span":{"begin":569,"end":595},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T28","span":{"begin":602,"end":628},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T29","span":{"begin":1120,"end":1146},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T30","span":{"begin":1169,"end":1195},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T31","span":{"begin":1289,"end":1315},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T32","span":{"begin":1417,"end":1443},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T33","span":{"begin":1585,"end":1611},"obj":"HGNC:IGF1"},{"id":"PD-PreeclampsiaGenes-B_T34","span":{"begin":64,"end":106},"obj":"HGNC:IGFBP7"},{"id":"PD-PreeclampsiaGenes-B_T35","span":{"begin":279,"end":321},"obj":"HGNC:IGFBP7"},{"id":"PD-PreeclampsiaGenes-B_T36","span":{"begin":602,"end":644},"obj":"HGNC:IGFBP7"},{"id":"PD-PreeclampsiaGenes-B_T37","span":{"begin":1120,"end":1162},"obj":"HGNC:IGFBP7"},{"id":"PD-PreeclampsiaGenes-B_T38","span":{"begin":1289,"end":1331},"obj":"HGNC:IGFBP7"},{"id":"PD-PreeclampsiaGenes-B_T39","span":{"begin":1585,"end":1627},"obj":"HGNC:IGFBP7"},{"id":"PD-PreeclampsiaGenes-B_T40","span":{"begin":64,"end":106},"obj":"HGNC:IGFBP3"},{"id":"PD-PreeclampsiaGenes-B_T41","span":{"begin":279,"end":321},"obj":"HGNC:IGFBP3"},{"id":"PD-PreeclampsiaGenes-B_T42","span":{"begin":602,"end":644},"obj":"HGNC:IGFBP3"},{"id":"PD-PreeclampsiaGenes-B_T43","span":{"begin":1120,"end":1162},"obj":"HGNC:IGFBP3"},{"id":"PD-PreeclampsiaGenes-B_T44","span":{"begin":1289,"end":1331},"obj":"HGNC:IGFBP3"},{"id":"PD-PreeclampsiaGenes-B_T45","span":{"begin":1585,"end":1627},"obj":"HGNC:IGFBP3"},{"id":"PD-PreeclampsiaGenes-B_T46","span":{"begin":64,"end":106},"obj":"HGNC:IGFBP2"},{"id":"PD-PreeclampsiaGenes-B_T47","span":{"begin":279,"end":321},"obj":"HGNC:IGFBP2"},{"id":"PD-PreeclampsiaGenes-B_T48","span":{"begin":602,"end":644},"obj":"HGNC:IGFBP2"},{"id":"PD-PreeclampsiaGenes-B_T49","span":{"begin":1120,"end":1162},"obj":"HGNC:IGFBP2"},{"id":"PD-PreeclampsiaGenes-B_T50","span":{"begin":1289,"end":1331},"obj":"HGNC:IGFBP2"},{"id":"PD-PreeclampsiaGenes-B_T51","span":{"begin":1585,"end":1627},"obj":"HGNC:IGFBP2"},{"id":"PD-PreeclampsiaGenes-B_T52","span":{"begin":64,"end":106},"obj":"HGNC:IGFBP4"},{"id":"PD-PreeclampsiaGenes-B_T53","span":{"begin":279,"end":321},"obj":"HGNC:IGFBP4"},{"id":"PD-PreeclampsiaGenes-B_T54","span":{"begin":602,"end":644},"obj":"HGNC:IGFBP4"},{"id":"PD-PreeclampsiaGenes-B_T55","span":{"begin":1120,"end":1162},"obj":"HGNC:IGFBP4"},{"id":"PD-PreeclampsiaGenes-B_T56","span":{"begin":1289,"end":1331},"obj":"HGNC:IGFBP4"},{"id":"PD-PreeclampsiaGenes-B_T57","span":{"begin":1585,"end":1627},"obj":"HGNC:IGFBP4"},{"id":"PD-PreeclampsiaGenes-B_T58","span":{"begin":64,"end":106},"obj":"HGNC:IGFBP5"},{"id":"PD-PreeclampsiaGenes-B_T59","span":{"begin":279,"end":321},"obj":"HGNC:IGFBP5"},{"id":"PD-PreeclampsiaGenes-B_T60","span":{"begin":602,"end":644},"obj":"HGNC:IGFBP5"},{"id":"PD-PreeclampsiaGenes-B_T61","span":{"begin":1120,"end":1162},"obj":"HGNC:IGFBP5"},{"id":"PD-PreeclampsiaGenes-B_T62","span":{"begin":1289,"end":1331},"obj":"HGNC:IGFBP5"},{"id":"PD-PreeclampsiaGenes-B_T63","span":{"begin":1585,"end":1627},"obj":"HGNC:IGFBP5"}],"text":"Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.\nOBJECTIVE: The purpose of this study was to determine the concentrations of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in pregnancies that are complicated with primary antiphospholipid syndrome.\nSTUDY DESIGN: Longitudinal blood samples were collected from 8 weeks of gestation in 28 women with treated primary antiphospholipid syndrome and 19 control women. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 were measured by immunoradiometric assay.\nRESULTS: Three antiphospholipid syndrome pregnancies miscarried, four pregnancies had intrauterine growth restriction and preeclampsia, six pregnancies had a thrombotic event, and one pregnancy had abruptio placentae. Mean (+/-SD) birth weight in antiphospholipid syndrome group was 2867 +/- 914 g (control, 3492 +/- 527 g; P =.02), and the mean gestation at delivery was 36.5 +/- 5.2 weeks (control, 40.3 +/- 0.7 weeks; P =.002). Insulin-like growth factor binding protein-1 and insulin-like growth factor-I concentrations increased with gestational age in both groups (2.8% and 2.4% per week), but insulin-like growth factor binding protein-1 was 61% higher in the antiphospholipid syndrome group (95% CI, 16%-122%; P =.004). Insulin-like growth factor-I was not significantly different (8% higher in antiphospholipid syndrome; 95% CI, -10% to 30%; P =.41).\nCONCLUSION: Serum concentrations of insulin-like growth factor binding protein-1 are abnormal in the antiphospholipid syndrome group and may reflect abnormalities in trophoblast invasion."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":427,"end":432},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":25,"end":30},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":240,"end":245},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":563,"end":568},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":1561,"end":1566},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":896,"end":905},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":1715,"end":1726},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"}],"text":"Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.\nOBJECTIVE: The purpose of this study was to determine the concentrations of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in pregnancies that are complicated with primary antiphospholipid syndrome.\nSTUDY DESIGN: Longitudinal blood samples were collected from 8 weeks of gestation in 28 women with treated primary antiphospholipid syndrome and 19 control women. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 were measured by immunoradiometric assay.\nRESULTS: Three antiphospholipid syndrome pregnancies miscarried, four pregnancies had intrauterine growth restriction and preeclampsia, six pregnancies had a thrombotic event, and one pregnancy had abruptio placentae. Mean (+/-SD) birth weight in antiphospholipid syndrome group was 2867 +/- 914 g (control, 3492 +/- 527 g; P =.02), and the mean gestation at delivery was 36.5 +/- 5.2 weeks (control, 40.3 +/- 0.7 weeks; P =.002). Insulin-like growth factor binding protein-1 and insulin-like growth factor-I concentrations increased with gestational age in both groups (2.8% and 2.4% per week), but insulin-like growth factor binding protein-1 was 61% higher in the antiphospholipid syndrome group (95% CI, 16%-122%; P =.004). Insulin-like growth factor-I was not significantly different (8% higher in antiphospholipid syndrome; 95% CI, -10% to 30%; P =.41).\nCONCLUSION: Serum concentrations of insulin-like growth factor binding protein-1 are abnormal in the antiphospholipid syndrome group and may reflect abnormalities in trophoblast invasion."}